The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

Moderna and BioNTech launched their initial public offerings ("IPOs") within one year of each other, with Modena raising $604m at $23 per share in December 2018, and BioNTech raising $150m at $15 ...

Moderna stock is worth ~39% more than BioNTech stock, which is a significant amount, but it has always been the higher valued company, and back in September 2021, it was worth 2x more than BioNTech.

Moderna is not asking that courts take the Pfizer-BioNTech COVID-19 vaccine off the market or to stop future sales, in view of the public need for the vaccines. Moderna and Pfizer's vaccines have ...

Moderna is suing Pfizer and BioNTech, alleging the companies copied its technology used to create their COVID-19 vaccine. The lawsuits were filed in Massachusetts and Germany.

Moderna said Friday, Aug. 26, 2022, that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, Spikevax.

COVID-19 vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.